SeraNovo Revenue and Competitors

Leiden,

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • SeraNovo's estimated annual revenue is currently $3.8M per year.(i)
  • SeraNovo's estimated revenue per employee is $201,000

Employee Data

  • SeraNovo has 19 Employees.(i)
  • SeraNovo grew their employee count by 19% last year.

SeraNovo's People

NameTitleEmail/Phone
1
Co-Founder and CEOReveal Email/Phone
2
Co-Founder and CEOReveal Email/Phone
3
Co-Founder & Chief Technology OfficerReveal Email/Phone
4
Co-FounderReveal Email/Phone
5
Chief Development OfficerReveal Email/Phone
6
Analytical scientistReveal Email/Phone
7
Business Development and Data Analysis AssociateReveal Email/Phone
8
Business Development and Data Analysis AssociateReveal Email/Phone
9
Senior Formulation ScientistReveal Email/Phone
10
Formulation ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$53.7M26716%N/AN/A
#2
$53.1M26421%N/AN/A
#3
$69.1M34426%N/AN/A
#4
$22.1M110-10%N/AN/A
#5
$151.8M75511%N/AN/A
#6
$63.9M31813%N/AN/A
#7
$29.9M14913%N/AN/A
#8
$1.7M17-6%$114.3MN/A
#9
$6.8M34-6%N/AN/A
#10
$12.5M62-9%N/AN/A
Add Company

What Is SeraNovo?

SeraNovo is a privately held Dutch pharmaceutical company with a proprietary technology platform to enhance the bioavailability of water insoluble drugs. SeraNovo's technology harnesses the unique benefits of deep eutectic solvents to create powerful, tailor-made solubility-enhancing formulations that are well tolerated and simple to produce. Since its incorporation in 2017, the company has secured multiple license deals, validating the potential of its technology. SeraNovo has a broad portfolio of programs progressing through clinical phases in 2021 and an established suit of intellectual property.

keywords:N/A

N/A

Total Funding

19

Number of Employees

$3.8M

Revenue (est)

19%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.7M1919%N/A
#2
$4.4M22-33%N/A
#3
$3.6M2310%N/A
#4
$2.5M2514%N/A
#5
$3.5M25108%N/A